This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Chin, B. B. Articles by Ladenson, P. Search for Related Content PubMed PubMed Citation Articles by Chin, B. B. Articles by Ladenson, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Nuclear Scans Thyroid Cancer Hazardous Substances DB THYROGLOBULIN

Recombinant Human Thyrotropin Stimulation of Fluoro-D-Glucose Positron Emission Tomography Uptake in Well-Differentiated Thyroid Carcinoma

Division of Nuclear Medicine, Department of Radiology (B.B.C., P.P., C.C., R.W., P.L.), and Division of Endocrinology and Metabolism, Department of Medicine (M.E., P.L.), Johns Hopkins University School of Medicine, Baltimore, Maryland 21287

Address all correspondence and requests for reprints to: Bennett B. Chin, M.D., Duke University School of Medicine, Department of Radiology, Division of Nuclear Medicine, Box 3949, DUMC Erwin Road–Duke North, Room 1410, Durham, North Carolina 27710. E-mail: chin0004{at}mc.duke.edu.

TSH stimulates thyrocyte metabolism, glucose transport, and glycolysis. 2-Deoxy-2-[18F]fluoro-D-glucose (FDG) is a glucose analog used in positron emission tomography (PET) to detect occult well-differentiated thyroid carcinoma. The objective of this study was to examine the effects of recombinant human TSH (rTSH) on FDG PET uptake in patients with residual or recurrent disease. Seven patients with well-differentiated thyroid carcinoma, negative 131-I scintigraphy, and biochemical evidence of residual disease were randomized and prospectively studied with FDG PET both on thyroid hormone suppression and rTSH stimulation within 1 wk. All lesions seen on the TSH suppression scans were seen on the rTSH stimulation studies. rTSH stimulation studies identified four additional lesions not seen on TSH suppression. One patient was positive on rTSH stimulation alone. The mean (2.54 ± 0.72 vs. 1.79 ± 0.88) and maximum (2.49 ± 0.95 vs. 1.74 ± 0.81) lesion to background ratios were significantly higher with rTSH stimulation, compared with TSH suppression (P = 0.02 for both). rTSH stimulation improves the detectability of occult thyroid metastases with FDG PET, compared with scans performed on TSH suppression.

This work was supported by Johns Hopkins University School of Medicine General Clinical Research Center, NIH/NCRR Grant M01 RR00052 (to B.B.C.).

Abbreviations: CT, Computed tomography; FDG, 2-deoxy-2-[18F]fluoro-D-glucose; 131-I, 131-iodine; L/B, lesion to background ratio; PET, positron emission tomography; rTSH, recombinant human TSH; SUV, standardized uptake value.

This article has been cited by other articles:

				K K WONG, N ZARZHEVSKY, J M CAHILL, K A FREY, and A M AVRAM Hybrid SPECT-CT and PET-CT imaging of differentiated thyroid carcinoma Br. J. Radiol., October 1, 2009; 82(982): 860 - 876. [Abstract] [Full Text] [PDF]

				O. Prante, S. Maschauer, V. Fremont, J. Reinfelder, R. Stoehr, M. Szkudlinski, B. Weintraub, A. Hartmann, and T. Kuwert Regulation of Uptake of 18F-FDG by a Follicular Human Thyroid Cancer Cell Line with Mutation-Activated K-Ras J. Nucl. Med., August 1, 2009; 50(8): 1364 - 1370. [Abstract] [Full Text] [PDF]

				S. Leboulleux, P. R. Schroeder, N. L. Busaidy, A. Auperin, C. Corone, H. A. Jacene, M. E. Ewertz, C. Bournaud, R. L. Wahl, S. I. Sherman, et al. Assessment of the Incremental Value of Recombinant Thyrotropin Stimulation before 2-[18F]-Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography/Computed Tomography Imaging to Localize Residual Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., April 1, 2009; 94(4): 1310 - 1316. [Abstract] [Full Text] [PDF]

				R. T. Kloos Approach to the Patient with a Positive Serum Thyroglobulin and a Negative Radioiodine Scan after Initial Therapy for Differentiated Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1519 - 1525. [Abstract] [Full Text] [PDF]

				M M Muresan, P Olivier, J Leclere, F Sirveaux, L Brunaud, M Klein, R Zarnegar, and G Weryha Bone metastases from differentiated thyroid carcinoma Endocr. Relat. Cancer, March 1, 2008; 15(1): 37 - 49. [Abstract] [Full Text] [PDF]

				F. Pacini, M. Schlumberger, H. Dralle, R. Elisei, J. W A Smit, W. Wiersinga, and the European Thyroid Cancer Taskforce European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol., June 1, 2006; 154(6): 787 - 803. [Full Text] [PDF]

				R. J. Robbins, Q. Wan, R. K. Grewal, R. Reibke, M. Gonen, H. W. Strauss, R. M. Tuttle, W. Drucker, and S. M. Larson Real-Time Prognosis for Metastatic Thyroid Carcinoma Based on 2-[18F]Fluoro-2-Deoxy-D-Glucose-Positron Emission Tomography Scanning J. Clin. Endocrinol. Metab., February 1, 2006; 91(2): 498 - 505. [Abstract] [Full Text] [PDF]

				E. L. Mazzaferri Empirically Treating High Serum Thyroglobulin Levels J. Nucl. Med., July 1, 2005; 46(7): 1079 - 1088. [Full Text] [PDF]

				R. J. Robbins and M. J. Schlumberger The Evolving Role of 131I for the Treatment of Differentiated Thyroid Carcinoma J. Nucl. Med., January 1, 2005; 46(1_suppl): 28S - 37S. [Abstract] [Full Text] [PDF]